Even with a decade plus of initiatives to increase racial and ethnic diversity in clinical trials for new medicines, today most trials do not enroll diverse populations. As a result, trial data does not reflect the people who take the medicines. At the 2022 Health Datapalooza and National Health Policy Conference, panelists discuss the federal guidance and private sector efforts and compare this to challenges to achieving diversity in data gathered for new drug approvals. The panel considers the need to go beyond guidance and establish regulatory incentives (expedited review, data exclusivity) for trial sponsors making good faith efforts to achieve diverse trials.

carmel headshot
Presenter

Kirsten Carmel, M.S.

Health Innovator Fellow - The Aspen Institute

Kirsten Carmel focuses on biopharma reimbursement and health policy and has worked with biopharmaceutical and ... Read Bio

amit bio
Presenter

Amrit Ray, MD, MBA

Chief Patent Officer - Biohaven

Amrit Ray, M.D., M.B.A. is a globally-experienced industry leader, physician researcher, and biopharmaceutical... Read Bio

Presenter

Percy Van Crocker, Jr., MBA

President and Founder - Agonist Health

Van Crocker has spent his 20+ year career driving innovation and change in the healthcare field, both in senio... Read Bio

David Bernstein headshot
Presenter

David Bernstein, Ph.D.

Senior Director, Science and Strategy - Stand Up To Cancer

David Bernstein is the Senior Director of Science and Strategy for Stand Up To Cancer and is based in New York. Read Bio